Abstract

Background: HIV self-testing (HIV-ST) is an innovative strategy to increase HIV case identification and can be implemented while maintaining physical distancing. This analysis shares the outcomes of HIV-ST implementation within the Zimbabwe HIV Care and Treatment (ZHCT) project and demonstrate the relevance of the results in bridging the HIV testing gap during the COVID-19 period and beyond.Methods: We extracted HIV-ST data for the period October 2018 to March 2020 from the project database and assessed 1)the proportion of reactive HIV-ST results; 2) the concordance between reactive HIV-ST results against rapid confirmatory HIV tests using Determine™ and Chembio™ in parallel; and 3) the monthly contribution of HIV-ST to total HIV positive cases identified within project. The Chi-square test was used to assess for differences in proportion of cases identified through HIV-ST and through index and mobile testing by age group, gender, and month.Findings: Between October 2018 and March 2020, the ZHCT project distributed 11,983 HIV-ST kits, where 11,924 (99·8%) were used and 2,616 (21·9%) were reactive. Of the reactive tests, 2,610 were confirmed HIV positive, a concordance rate of 99·8% between the HIV-ST results and the confirmatory tests. Proportion of reactive results differed by age-groups; with the 30-34, 35-39- and 40-44-year age groups having the highest proportions above 25% (pInterpretation: The ZHCT project has successfully scaled up HIV self-testing which is contributing significantly to HIV case finding. Given the current COVID-19 challenges these results demonstrate the potential of HIV-ST in closing the HIV testing gap because it can be implemented while maintaining physical distancing.Funding Statement: The ZHCT project is a six-year Presidential Emergency Plan for AIDS Relief (PEPFAR) funded project through the United States Agency for International Development (USAID).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: The study was reviewed and approved for non-research determination by the Medical Research Council of Zimbabwe (MRCZ/E/159).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call